SECTION I · THE BRIEF
Brief #83681Updated 19 AUG 2025REDWOOD CITY, CAGreenhouseKHOSLA VENTURES
Employbl Dossier

Earli Talent Community

Earli Inc. operates as a biotechnology company. The Company develops treatments to cure cancer. Earli serves patients in the State of California.

Location
Redwood City, CA
Company size
20–50
Posted
10mo ago
Via
Greenhouse
Section II · Premium ProfileMembers only
  • 01Comp band & equity packageLocked
  • 02Seniority & experience requirementsLocked
  • 03Interview process & rubricLocked
  • 04Hiring manager & team contextLocked
  • 05Growth trajectory in this roleLocked
  • 06Offer & decision timelineLocked

7-day free trial · $25/mo · cancel anytime

Earli logo

Earli Talent Community - Earli

View Company Profile
Job Title
Earli Talent Community
Job Location
Redwood City, CA
Job Description

Earli tackles the #1 problem in the $100B cancer drug market: systemic toxicity. On-target/off-tumor effects force suboptimal dosing, reduced efficacy and sidelining some of the most potent drug classes such as cytokines. Earli’s BioAI approach flips this paradigm: Drugs are produced only where needed—in the tumor, by the tumor, against the tumor. Cancer cells become their own drug factories, enabling localized immune activation, even in cold tumors.

This was enabled by three core innovations:

  1. Extrahepatic lipid nanoparticles (LNPs) that reach tumors such as lung cancer
  2. AI-designed genetic switches that activate only in malignant cells by sensing transcription factor dysregulation
  3. Local production of immune therapies (TCEs, cytokines, multispecifics) at the tumor site — “produce locally, consume locally”

Together, these technologies create a new biological control layer, allowing tumors to self-identify and trigger their own targeted immune attack—achieving specificity beyond current targeted or IO therapies.

Earli plans to enter the clinic by mid-2027 with a Phase 1/2 lung cancer trial. The company is backed by a16z, Khosla, Perceptive, Alex Gorsky, Marc Benioff, Breyer, Emerson Collective, Sands Capital and others. The SAB includes Jim Allison (Nobel Laureate, MD Anderson), Bob Langer (Co-founder Moderna, MIT), Phil Greenberg (Co-founder Juno), Amy Abernethy (frm. Principal Deputy FDA Commissioner), Bill Hait (former J&J EVP Oncology R&D), and Alan Ashworth (President UCSF Cancer Center). The leadership team brings deep gene therapy, LNP, CMC and tech experience; CEO Cyriac Roeding previously led a $250M (11x return) exit.

Who You Are

  • You share our same sense of dedication, scientific passion and entrepreneurial spirit 
  • You work well in a fast-paced and extremely focused startup environment 
  • You are not only smart, but clever and constantly think outside the box 
  • You are able to make logical decisions in an instant when there is little time to evaluate 
  • You are a natural communicator and relationship builder 
  • You stay calm under high pressure and stress 
  • You have the ability to multi-task in a serious way, with an extreme attention to detail 
  • You become a representative of the core DNA of the company through who you are 

The Position

This is a general submission form to join the Earli Talent Community. If you are interested in working at Earli but don't see a current opening that aligns with your skills and background we're always on the lookout for great people who are interested in working with us or who are interested in potential upcoming internship opportunities available in our lab.

If interested in applying, please attach a CV or have a well-developed LinkedIn profile for us to be able to assess your background. 

We look forward to hearing from you!

Get the Saturday tech briefing

New company profiles, funding moves, and who’s hiring across the market — every Saturday morning.

Where this role is based

Redwood City, CA

Loading map…

Earli Headquarters Location

South San Francisco, CA

View company profile

Earli Company Size

Between 20 - 50 employees

Earli Founded Year

2018

Earli Total Amount Raised

$59,900,000

Earli Funding Rounds

View funding details
  • Series Unknown

    $177,778 USD

  • Series A

    $967,500 USD

  • Series A

    $40,000,000 USD

  • Series A

    $40,000,000 USD

  • Seed

    $19,500,000 USD

  • Seed

    $19,500,000 USD

  • Pre Seed

    $400,000 USD

  • Pre Seed

    $400,000 USD